MeSH tree: C12.200.777.419.570.363.608
For patients with immunoglobulin A (IgA) nephropathy, nine months of treatment with targeted-release formulation of budesonide (Nefecon) yields a greater reduction in estimated glomerular filtration rate (eGFR) than placebo, ...
Aug 22, 2023
0
1
The cause of a common kidney disease likely lies outside the kidney, according to a new study led by Columbia University researchers. The study, which uncovered 16 new locations in the genome linked to immunoglobulin A (IgA) ...
Jun 23, 2023
0
33
Urine is one of the attractive sources for early and sensitive biomarker discovery since it can accumulate and reflect changes in the human body while being collected non-invasively. However, analysis of the urine proteome ...
Jun 16, 2023
0
2
Swiss pharmaceutical giant Novartis said Monday that it had reached a deal to buy US kidney treatment developer Chinook Therapeutics for up to $3.5 billion.
Jun 12, 2023
0
2
The latest findings from the PROTECT phase III trial show sparsentan—a novel treatment for IgA nephropathy—significantly reduces proteinuria, or abnormal protein levels in the urine, compared to standard treatment irbesartan.
Apr 3, 2023
0
78
IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney. In advanced stages of the disease, the buildup ...
Mar 22, 2023
0
80
Increased levels of the antibody immunoglobulin A (IgA) are correlated with the manifestation of several diseases as well as African ancestry, according to findings published in Nature Communications. The findings provide ...
Jan 5, 2023
0
72
Some cytokines can enhance the production of aberrantly O-glycosylated IgA1, the main autoantigen in IgA nephropathy. The mechanism behind this observation is described in the Journal of Interferon & Cytokine Research (JICR).
Jul 19, 2022
0
5
